ZURICH (Reuters) - An experimental drug from Novartis markedly shrank tumors in patients with advanced basal cell carcinoma, the most common form of skin cancer, according to the results of a mid-stage study published on Sunday.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
Lake forest health and fitness http://ift.tt/1wNCoPC
No comments:
Post a Comment